Targeted inorganic nanodevices for breast cancer diagnosis and therapy Fiandra Luisa Nanomedicine Laboratory Luigi Sacco University Hospital Milan Italy.

Slides:

Advertisements

Similar presentations

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Advertisements

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Nanoscale Imaging Probes for Personalized Medicine Undergraduate Researchers Leslie Chan, Rahul Balusu and Alice Chan Mentors Efstathios Karathanasis,

Nanomedicines for diagnosis and therapy. Nanomedicines.

Characterization of delivery systems for nanomedicine Dr. John A. Dagata.

Challenges in Clinical Applications for Nanotechnology N. Tony Eissa, MD Table 3.

Nanomedicine and Cancer Joseph Abel Department of Physics, USU.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Therapeutic Implications and Prognostic Significance of c-Met in Esophageal Squamous Cell Cancer Ching Tzao 1, Chun-Ya Wang 1, Ban-Hen Chen 1, Guang-Huan.

Nanoparticles and their medical applications

2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!

Targeted Gold Nanoparticles as Vascular Disrupting Agents during Radiation Therapy RI Berbeco 1, H Korideck 1, S Kunjachan 1, R Kumar 2, S Sridhar 2, A.

Gianni L et al. Proc SABCS 2012;Abstract GS6-7.

Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology.

Presented By: Lana Awad and Sebastian Lukjan. Motivation of research, why they did what they did…  Understand steps that cancer cells take to spread.

Bioreducible cross-linked polymer coated mesoporous silica nanoparticles for targeted delivery of siRNA to HER2+ breast cancer Nanotek & Expo, San Francisco,

NANOMEDICINE A.A An expanding field, Nanomedicine represents an active field of pharmacological research. However, only a small part of nanodrugs.

FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

NANOTECHNOLOGIES: THE NEW GENERATION OF MEDICINE Dr Mariano Licciardi.

Expressing Surface Proteins to Target Cancer Cells Joe and Bobby.

Nanotechnology in Cancer Treatment

Antibody and prodrug therapy of cancer

MAGNETIC NANOASSEMBLIES in MEDICINE

Dr. Sheila Singh’s Laboratory Lab overview Operating since August 2007 Located at the Stem Cell & Cancer Research Institute at McMaster Main Campus Research.

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

 Nanotechnology is the study of particles 1x10 ^-9 of a meter in size.  Over the past decade the field has gained tremendous ground, including nanomedicine.

LPPD University of Illinois Chicago, LPPP. Summer 2008 Magnetically-Guided Nanoparticles for Targeted Drug Delivery Presentation for RET program June 30,

Nanomedicines. Nanomedicines for diagnosis and therapy.

Cancer Historically agents given systemically – Agents that kill rapidly dividing cells Find therapeutic dose  Kills tumor cells w/o killing patient –

Nanoparticles for Medical and Surgical Tumor Therapy Departments of Radiology, Oncology and Biomedical Engineering Emory University School of Medicine.

Molecular Biomarkers & Targets an overview Michael Messenger NIHR Diagnostic Evidence Co-Operative & Leeds Cancer Research UK Centre.

By: Joanne Pugliese. Nanotechnology is the science and study of particles at a molecular or atomic level. Manipulation of molecules at the atomic level.

NANOTECHNOLOGY IN CANCER TREATMENT

Targeting of reactive oxygen species can be a potential therapeutic strategy for cancer treatment Ying-Ray Lee 1, San-Yuan Chen 2, and Hau-Ren Chen 3 1.

Convergence of Nanotechnology and Cardiovascular Medicine Harsharan Pal Singh 1 *, Ishpreet Kaur 2 1 Department of Pharmacology & Toxicology, Noida Institute.

LPPD University of Illinois Chicago, LPPP. Summer 2008 Magnetically-Guided Nanoparticles for Targeted Drug Delivery Presentation for RET program July 7,

دکترعلی شاکری زاده پنجمین جلسه ژورنال کلاب

Nanomedicine Research at OU

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

Anti-tumor effects of combination resveratrol

Department of Applied Chemistry, Kyung Hee University

Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy Shengpeng.

MAGNETIC NANOCOMPOSITE PARTICLES FOR BIO-APPLICATIONS

Opportunities for Addressing Unmet Clinical Need in Brain Cancer

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health

Project Promoter: University of Tartu

iRGD, a tumor-penetrating peptide for tumor-specific drug delivery

Table 1. Scientific findings of previously published work on Graviola

excellent contrast agents for imaging and labels for bioassays.

Production and clinical development of nanoparticles for gene delivery

Eric Laywell Biomedical Sciences

سرطان الثدي Breast Cancer

Figure 1 Cellular processes involved in cancer development

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Figure 3 Intracranial targeting of high-grade gliomas

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health

Gold Nanorods/Nanoparticles: Mechanisms, Application and Toxicity

Matriptase-2 inhibited breast tumor development in vivo.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

The efficacy of telomerase inhibition–based therapies, such as imetelstat, depends on the tumor telomere length at the beginning of treatment. The efficacy.

Possible outcomes of therapeutic treatments using the spiral model.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

mRNA expression of PARP1 in SCLC cell lines and solid tumors.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Power THE FUTURE OF FIGHTING CANCER

Presentation transcript:

Targeted inorganic nanodevices for breast cancer diagnosis and therapy Fiandra Luisa Nanomedicine Laboratory Luigi Sacco University Hospital Milan Italy Department of Biomedical and Clinical Sciences “L. Sacco” University of Milan Milan Italy NanoBioLab Department of Biotechnology and Biosciences University of Milan-Bicocca

NANOMEDICINE MRI CONTRAST AGENT GENE THERAPY PHOTO-THERMAL THERAPY HYPERTHERMIA ANTIBODY-BASED THERAPY DRUG DELIVERY

NANO-ONCOLOGY

TARGETING CANCER CELLS BY SPECIFIC INTERACTION WITH HER2 HER2: Human Epidermal growth factor Receptor 2 (HER2) II. GOLD NP (KLONDY) I. IRON OXIDE NPs

I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER FITC-TZ-magnetic nanocrystals (TMNC) Mazzucchelli S., et al. ACSNano, 2010

Corsi F., et al. ACSNano, 2011 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER AF660-TMNC

5h 24h 1 w I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER Corsi F., et al. ACSNano, 2011 AF660-TMNC

Fiandra F., et al. ACSNano, 2013 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER FITC-magnetic nanoparticles (MNP)

IN VIVO TARGETING OF HER2-POSITIVE TUMORS Fiandra F., et al. ACSNano. 2013; 7; I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER AF660-TZ/HC/scFv-MNP

Fiandra F., et al. ACSNano. 2013; 7; I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER AF660-TZ/HC/scFv-MNP

Corsi F., et al. ACSNano I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER IN VIVO DIAGNOSTIC POTENTIAL: INCREASE OF NEGATIVE CONTRAST Pre-injection TMNC Post-injection TMNC

I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER IN VIVO THERAPEUTIC POTENTIAL: DECREASE OF HER2 EXPRESSION NT TMNC 5h TMNC 48h TMNC 24h Corsi F., et al. ACSNano. 2011

II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER 2% AGAROSE GEL MONO- OR BI-FUNCTIONALIZED GOLD NP (KLONDY) Colombo M, Fiandra F., et al. Nature Communications under review

II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER In vitro interaction with HER2+ MCF-7 breast cancer cells Colombo M, Fiandra F., et al. Nature Communications under review 1 h, 37 °C FITC-1Tz/2Tz-NP

II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER Higher accumulation in tumor of 1TZ vs 2TZ-NP in vivo Mean t 1/2 (h)SD Colombo M, Fiandra F., et al. Nature Communications under review n = 3 AF660-1TZ/2TZ-NP

Colombo M, Fiandra F., et al. Nature Communications under review AF660-1TZ/2TZ -NP II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER Anti-CK19

II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER IN VIVO THERAPEUTIC EFFECT OF K1/K2-TZ VS FREE TZ 96 h sustained therapeutic effect over time only with K1-Tz Less is More !!!! Colombo M, Fiandra F., et al. Nature Communications under review

Acknowledgements Department of Biomedical and Clinical Sciences «L. Sacco» University of Milan Nanomedicine Laboratory «L. Sacco» University Hospital Milan NanoBioLab Department of Biotechnology and Biosciences University of Milan-Bicocca NanoMeDia Project